Solid Biosciences Inc.

SLDB ·Healthcare, Drug Manufacturers - General, United States
Financial Statements Income Statement
Annual Quarterly

Income Statement

Line Item Dec 2020 Sep 2020 Jun 2020 Mar 2020 Dec 2019 Sep 2019 Jun 2019 Mar 2019
Revenue $0 $0 $0 $0 $0 $0 $0 $0
Cost of Revenue
Gross Profit
Gross Margin
Operating Expenses
Research & Development $15.7M $16.0M $13.4M $19.7M $27.1M $22.8M $21.6M $23.3M
SG&A Expense $5.6M $5.2M $5.5M $5.3M $5.3M $6.9M $5.4M $7.0M
Operating Income $-21.3M $-21.2M $-19.0M $-26.9M $-32.3M $-29.7M $-27.0M $-30.3M
Operating Margin
Interest Expense
Pretax Income
Income Tax Expense $0 $0 $0 $0 $0 $0 $0 $0
Net Income $-21.4M $-21.2M $-19.0M $-26.7M $-31.9M $-29.3M $-26.5M $-29.6M
Net Margin
EPS (Basic) $-1.51 $-0.03 $-0.02 $-0.04 $-0.04 $-0.04 $-0.05 $-0.05
EPS (Diluted) $-1.51 $-0.03 $-0.02 $-0.04 $-0.04 $-0.04 $-0.05 $-0.05
Shares Outstanding (Basic) 1.36B 738.9M 735.8M 737.1M 735.8M 736.0M 566.4M 566.6M
Shares Outstanding (Diluted) 1.36B 738.9M 735.8M 737.1M 735.8M 736.0M 566.4M 566.6M
Dividends Per Share
← Newer Page 1 of 2 Older →